Appointment of Daniel J. O'Connor as CEO of Jubilant Therapeutics Inc.

Jubilant Pharmova Limited announces the appointment of Daniel J. O'Connor as the CEO of its Proprietary Novel drugs business (Jubilant TherapeuticsInc.).

Dan brings more than 30 years of leadership experience in Biotechnology and Oncology, with a proven record of creating value around differentiated, IP-rich platforms. Most recently, he served as CEO of Ambrx Biopharma, where his leadership drove a significant increase in company valuation culminating in its successful acquisition.

Earlier in his career, Dan was instrumental at ImClone Systems, contributing to the clinical development, launch, and commercialization of a major oncology therapy while navigating complex intellectual property and inventorship challenges. He also served as CEO of Advaxis, a NASDAQ-listed immuno-oncology company, where he transformed the organization into a late-stage clinical enterprise, secured substantial growth capital, and forged strategic collaborations with leading pharmaceutical partners.

Commenting on the occasion, Mr. Shyam S. Bhartia, Chairman and Mr. Hari S. Bhartia, Co-Chairman, Jubilant Pharmova Limited, said, "We are delighted to welcome Dan as we advance our mission of building a clinical-stage therapeutics company focused on developing innovative therapies across multiple cancer indications."

On the Occasion, Mr. Daniel J. O'Connor, said, "I am honoured to lead Jubilant Therapeutics, a company dedicated to driving breakthrough innovation for cancers that are difficult to treat. I look forward to collaborating closely with our talented team to advance our mission and deliver meaningful value to patients, partners, and stakeholders alike."

Shares of Jubilant Pharmova Limited was last trading in BSE at Rs. 1106.85 as compared to the previous close of Rs. 1091.55. The total number of shares traded during the day was 14862 in over 943 trades.

The stock hit an intraday high of Rs. 1110.45 and intraday low of 1086.15. The net turnover during the day was Rs. 16399015.00.

Source : Equity Bulls

Keywords

JubilantPharmova INE700A01033 Pharmaceuticals JubilantTherapeuticsInc Appointment CEO